Gland Pharma shares soar 20% after upbeat Q1 result and strong future outlook

Gland Pharma shares are flying high on the back of strong results and a strong guidance as they hit the upper circuit of 20 per cent at Rs 1,612.60 on the BSE today (August 8). 

After the company's results were announced on Monday evening, Jefferies took a u-turn and upgraded the company's stock from to 'buy' from 'underperform' and raised its price trarget to Rs 1,640. 

Jefferies said about Gland Pharma's Q1 performance, "Results are good, USA product pricing is improving, and the company is also set to launch new products."

Zee Business managing editor Anil Singhvi gave a buy call to Gland Pharma shares with a stop loss at Rs 1,300 for targets of Rs 1,375, Rs 1,390, Rs 1,400, and Rs 1,425.

He says that the company is improving on a number of parameters. "Results are better in all parameters; its USA product pricing is improving; the company is set to launch new products; and oversold pharma stocks are ready for a big upside," said Singhvi.

Gland Pharma Q1 Results 

In the results announced Monday evening, Gland Pharma reported a 41 per cent jump in its revenues.

The company clocked a revenue of Rs 1,208.6 crore in the quarter under review against Rs 856.89 crore in the year-ago period.

However, the company's profits were down 15.2 per cent to Rs 194 crore against Rs 229 crore in the corresponding period last year. 

The company's EBIDTA jumped to Rs 294 crore against Rs 270 crore in the first quarter last year.

The EBIDTA margin was at 24.3 per cent in comparison to 31.5 per cent in the corresponding period last year.